3M Didn't Take Responsibility. A Bankruptcy Judge and Six Times Its Opening Offer Did.

A 3M toxicologist looked at the company's own data and wrote it down in capital letters: the chemicals were 'VERY persistent and thus insidiously toxic.' He had calculated a safe level in human blood of about 1.05 parts per billion. 3M had already measured roughly 30 parts per billion circulating in the general population — thirty times his own ceiling.⁷ The company kept making the chemical anyway, for years. That memo is the real opening of 3M's defining crisis. The press releases came decades later, and they are written in a very different voice.

The official story is that 3M faced a hard problem, acted responsibly, exited PFAS, and settled with the people it had harmed. The real story is that 3M suppressed the evidence as long as it could, fought the science, tried a courtroom maneuver to cap its liability cheaply — and only paid up when judges took the maneuver apart and left it no exit. What looks like accountability was the bill arriving after every cheaper option had been struck down.

Read the exit statement. It never says the chemicals were dangerous.

On December 20, 2022, 3M announced it would exit all PFAS manufacturing by the end of 2025 and stop using PFAS across its product portfolio. The chemicals were a roughly $1.3 billion annual business; the company took a pre-tax charge of about $0.8 billion for the related asset impairments.¹² If you want to know whether this was an act of conscience, read the language. The stated drivers were 'regulatory trends' and 'changing stakeholder expectations.' The chief executive's framing held that PFAS 'can be safely made and used.'¹ That is the grammar of a company managing risk, not admitting harm. A firm that believed its product was poisoning the public would not insist, in the same breath, that it could be made safely. It would not call the reason for leaving 'regulatory trends.' It would call it a duty. 3M called it a portfolio decision.

And it was a portfolio decision, because by late 2022 the math had flipped. A peer-reviewed study based on 39 internal industry documents dating back to 1961 concluded that 3M and DuPont had actively suppressed evidence of PFAS hazards since the 1960s — including learning, in 1980, of birth defects in children of pregnant PFAS workers and disclosing it to no one.⁶ A federal judge had just refused to hand 3M blanket immunity in the firefighting-foam litigation, citing internal memos suggesting the company hid PFAS risks from customers, including the government.⁷ Regulation was tightening worldwide. When the cost of staying exceeds $1.3 billion in revenue, you stop. That is not leadership. That is arithmetic.

The bankruptcy gambit that multiplied the bill by six

The earplug crisis shows the strategy with no ambiguity at all. 3M had sold Combat Arms earplugs that veterans say failed; tens of thousands of claims were consolidated into a mass tort centralized in April 2019 in federal court in Florida.⁴ Facing that exposure, 3M did not negotiate. On July 26, 2022 it ordered its subsidiary Aearo Technologies into Chapter 11 bankruptcy, proposing a settlement fund of roughly $1 billion.⁵ The logic was elegant and cynical: push the liability into a bankrupt shell, freeze the lawsuits, and cap the payout at a number 3M chose. It is the same playbook other corporations have used to wall off mass-tort claims behind a subsidiary that conveniently has no future.

It did not work. On June 9, 2023, a bankruptcy judge threw the filing out, ruling that Aearo was financially healthy and the Chapter 11 served 'no valid reorganization purpose.'⁵ You cannot use bankruptcy to escape liability when you are not actually going bankrupt. With the shield shattered and an appeal abandoned, 3M settled in August 2023 — for up to $6 billion.⁴ The dismissal of the bankruptcy directly caused the settlement to multiply: roughly six times the company's opening offer.⁵ The gambit didn't reduce 3M's bill. It announced 3M's bottom line to every plaintiff's lawyer in the country, then forced the company to pay six times it.

The same pattern, written across two crises

Stack the two stories and the shape is identical. First, internal knowledge of harm held quietly for years — PFOS in the public's blood understood in the 1970s, the chemical produced by the tens of millions of pounds and manufactured until 2000.⁸ Then deflection: in 2006 the EPA accused 3M of repeatedly failing to disclose fluorochemical harms under the federal toxics law; 3M paid a $1.5 million penalty without admitting wrongdoing.⁸ Then, when litigation turned existential, an attempt to control the cost on 3M's own terms — a worded-just-so exit announcement, a bankruptcy filing. And only after courts and class actions stripped those options away did the real money move: $10.3 billion in present value to public water suppliers (a maximum of $12.5 billion over time), finalized in 2024.³ Accountability was the last resort, not the first instinct.

The honest counter: isn't paying $16 billion accountability anyway?

The fair objection is that motive shouldn't matter. 3M is paying out more than $16 billion across the two crises and is leaving the PFAS business entirely. Water gets cleaner; veterans get compensated. Does it really matter that courts forced the hand rather than conscience? It matters for one reason: motive predicts behavior in the cases not yet litigated. A company that pays because it was caught will keep the next problem buried exactly as long as it can — and 3M's record runs from the 1960s to the EPA penalty to the bankruptcy gambit without a break. There is also a quieter tell in the fine print. 3M's 'exit' applies to manufacturing PFAS raw materials; it leaves the company free to keep using PFAS sourced from third parties in finished products. The exit is narrower than the headline, and the headline is the point. When the contrition is engineered by a judge and the press release is drafted to admit nothing, you have not bought a reformed company. You have bought a settled invoice.

3M's defining crisis is taught, increasingly, as a comeback — the company that faced its forever-chemical reckoning and did the right thing. Strip the framing away and a colder story remains: a firm that knew for decades, said nothing, fought the science, tried to wall the bill off inside a healthy subsidiary it pretended was sick, and paid six times its offer only after a judge refused the trick. The genius of the modern crisis response is not in handling the crisis. It is in narrating the surrender so that capitulation reads like character. 3M didn't take responsibility. It ran out of ways not to — and learned the price of finding out in public.